327 related articles for article (PubMed ID: 29739753)
1. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Zimmerman Z; Cannell P; Dombret H; Maertens J; Stein A; Franklin J; Tran Q; Cong Z; Schuh AC
Blood; 2018 Jun; 131(26):2906-2914. PubMed ID: 29739753
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
3. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Rambaldi A; Ritchie EK; Papayannidis C; Tuglus CA; Morris JD; Stein A
Eur J Cancer; 2021 Mar; 146():107-114. PubMed ID: 33588145
[TBL] [Abstract][Full Text] [Related]
5. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H; Stein A; Gökbuget N; Fielding AK; Schuh AC; Ribera JM; Wei A; Dombret H; Foà R; Bassan R; Arslan Ö; Sanz MA; Bergeron J; Demirkan F; Lech-Maranda E; Rambaldi A; Thomas X; Horst HA; Brüggemann M; Klapper W; Wood BL; Fleishman A; Nagorsen D; Holland C; Zimmerman Z; Topp MS
N Engl J Med; 2017 Mar; 376(9):836-847. PubMed ID: 28249141
[TBL] [Abstract][Full Text] [Related]
6. Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.
Barlev A; Lin VW; Katz A; Hu K; Cong Z; Barber B
Adv Ther; 2017 Jan; 34(1):148-155. PubMed ID: 27873237
[TBL] [Abstract][Full Text] [Related]
7. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
9. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
Dombret H; Topp MS; Schuh AC; Wei AH; Durrant S; Bacon CL; Tran Q; Zimmerman Z; Kantarjian H
Leuk Lymphoma; 2019 Sep; 60(9):2214-2222. PubMed ID: 30947585
[TBL] [Abstract][Full Text] [Related]
10. VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
Heraudet L; Galtier J; Favre S; Peyraud F; Cazaubiel T; Leroy H; Mottal N; Gros FX; Forcade E; Clément L; Dumas PY; Pigneux A; Leguay T
Br J Haematol; 2022 Aug; 198(3):523-527. PubMed ID: 35524489
[TBL] [Abstract][Full Text] [Related]
11. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
Topp MS; Stein AS; Gökbuget N; Horst HA; Boissel N; Martinelli G; Kantarjian H; Brüggemann M; Chen Y; Zugmaier G
Cancer Med; 2021 Apr; 10(8):2601-2610. PubMed ID: 33734596
[TBL] [Abstract][Full Text] [Related]
12. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
Gökbuget N; Dombret H; Giebel S; Brüggemann M; Doubek M; Foa R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Maria Ribera J; Schoonen M; Tuglus C; Zugmaier G; Bassan R
Eur J Haematol; 2020 Apr; 104(4):299-309. PubMed ID: 31876009
[TBL] [Abstract][Full Text] [Related]
14. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia.
Stein AS; Larson RA; Schuh AC; Stevenson W; Lech-Maranda E; Tran Q; Zimmerman Z; Kormany W; Topp MS
Blood Adv; 2018 Jul; 2(13):1522-1531. PubMed ID: 29954814
[TBL] [Abstract][Full Text] [Related]
15. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
[TBL] [Abstract][Full Text] [Related]
16. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J
Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952
[TBL] [Abstract][Full Text] [Related]
20. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]